AR052506A2 - Intermediarios utiles para la preparacion de compuestos heterociclicos - Google Patents
Intermediarios utiles para la preparacion de compuestos heterociclicosInfo
- Publication number
- AR052506A2 AR052506A2 ARP060100824A ARP060100824A AR052506A2 AR 052506 A2 AR052506 A2 AR 052506A2 AR P060100824 A ARP060100824 A AR P060100824A AR P060100824 A ARP060100824 A AR P060100824A AR 052506 A2 AR052506 A2 AR 052506A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- independently
- optionally
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 20
- -1 1H-tetrazol-5-yl Chemical group 0.000 abstract 9
- 229920006395 saturated elastomer Polymers 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Cooling Or The Like Of Electrical Apparatus (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto intermediario util en la preparacion de un compuesto de acuerdo con la formula (1) por ser de la formula (2) las mezclas racémicas-diastereoméricas y los isomeros opticos de dichos compuestos y las sales farmacéuticamente aceptables de los mismos, en la que e es 0 o 1; n y w son cada uno de forma independiente 0, 1 o 2, con la condicion de que w y n no pueden ser ambos 0 al mismo tiempo; R1 es h, -CN, -(CH2)qN(X6)C(O)X6, -(CH2)qN(X6)C(O)(CH2)t-A1, -(CH2)qN(X6)SO2(CH2)t-A1, - (CH2)qN(X6) SO2X6, -(CH2)qN(X6)C(O)N(X6)(CH2)t-A1, -(CH2)qN(X6)C(O)N(X6)(X6), -(CH2)qC(O)N(X6)(X6), -(CH2)qC(O)N(X6)(CH2)t-A1, -(CH2) qC(O)OX6, -(CH2)qC(O)O(CH2)t-A1, -(CH2)qOX6, -(/CH2)qOC(O)X6, -(CH2)qOC(O)(CH2)t-A1, -(CH2)qOC(O)N(X6)(CH2)t-A1, - (CH2) qOC(O)N(X6)(X6), -(CH2)qC(O)X6, -(CH2)qC(O)(CH2)t-A1, -(CH2)qN(X6)C(O)OX6, -(CH2)qN(X6)SO2N(X6)(X6), -(CH2)qS(O)mX6, -(CH2)qS(O)m(CH2)t-A1, -alquilo C1-10, -(CH2)t-A1, -(CH2)q-cicloalquilo C3-7, -(CH2)q-Y1-alquilo C1-6, -(CH2)q-Y1-(CH2)t-A1 o - (CH2)q-Y1-(CH2)t-cicloalquilo C3-7, donde los grupos alquilo y cicloalquilo en la definicion de R1 están sustituidos opcionalmente con alquilo C1-4, hidroxilo, alcoxilo C1-4, carboxilo, CONH2, -S(O)m-alquilo C1-6, -CO2alquil C1-4, 1H-tetrazol-5-ilo o 1 átomo de F; Y1 es O, S(O)m, -C(O)NX6-, -CH=CH-, -C:::C-, -N(X6)C(O)-, -C(O)NX6-, -C(O)O-, -OC(O)N(X6)- o -OC(O)-, q es 0, 1, 2, 3 o 4; t es 0, 1, 2 o 3; el grupo (CH2)q y el grupo (CH2)t citados podrían estar cada uno sustituido opcionalmente con 1 a 3 átomos de F, 1 o 2 alquilos C1-4, hidroxilo, alcoxilo C1-4, carboxilo, -CONH2, -S(O)m-alquilo C1-6, éster-CO2alquil C1-4 o 1H-tetrazol-5-ilo; R2 es H, alquilo C1-8, - alquil C0-3-cicloalquilo C3-8, -alquil C1-4-A1 o A1; donde los grupos alquilo y los grupos cicloalquilo de la definicion de R2 están sustituidos opcionalmente con hidroxilo, -C(O)OX6, -C(O)N(X6)(X6), -N(X6)(X6), -S(O)m-alquilo C1-6, -C(O)A1, -C(O)(X6), CF3, CN o 1 a 3 átomos de halogeno; A1 cada vez que se da es de forma independiente cicloalquenilo C5-7, fenilo o un anillo de 4 a 8 miembros parcialmente saturado, completamente saturado o completamente insaturado que tiene 1 a 4 heteroátomos seleccionados de forma independiente del grupo formado por O, S y N, un sistema de un anillo bicíclico formado por un anillo de 5 o 6 miembros parcialmente saturado, completamente insaturado o completamente saturado, que tiene opcionalmente 1 a 4 heteroátomos seleccionados de forma independiente del grupo formado por N, S y O, fusionado a un anillo de 5 o 6 miembros parcialmente saturado, completamente insaturado o completamente saturado, que tiene opcionalmente 1 a 4 heteroátomos seleccionados de forma independiente del grupo formado por N, S y O; A1 cada vez que se da está sustituido opcionalmente de forma independiente, en uno u opcionalmente en ambos anillos si A1 es un sistema de un anillo bicíclico, con hasta 3 sustituyentes, seleccionados cada sustituyente de forma independiente del grupo formado por F, Cl, Br, I, OCF3, OCF2H, CF3, CH3, OCH3, -OX6, -C(O)N(X6)(X6), -C(O)OX6, oxo, alquilo C1-6, nitro, ciano, bencilo, -S(O)m-alquilo C1-6, 1H-tetrazol-5-ilo, fenilo, fenoxilo, fenilalquiloxilo, halofenilo, metilendioxilo, -N(X6)(X6), - N(X6)C(O)X6, - SO2N(X6)(X6), -N(X6)SO2-fenilo, -N(X6)SO2X6, -CONX11X12, -SO2NX11X12, -NX6SO2X12, -NX6CONX11X12, -NX6SO2NX11X12, - NX6C(O)X12, imidazolilo, tiazolilo y tetrazolilo, con la condicion de que si A1 está sustituido opcionalmente con metilendioxilo entonces solo puede estar sustituido con un metilendioxilo; donde X11 es H o alquilo C1-6 opcionalmente sustituido; el alquilo C1-6 opcionalmente sustituido definido para X11 está sustituido opcionalmente de forma independiente con fenilo, fenoxilo, alcoxicarbonilo C1-6, -S(O)m-alquilo C1-6, 1 a 5 halogenos, 1 a 3 hidroxilos, 1 a 3 alcanoiloxilos C1-10 o 1 a 3 alcoxilos C1-6; X12 es H, alquilo C1-6, fenilo, tiazolilo, imidazolilo, furilo o tienilo, con la condicion de que cuando X12 no es H, X12 está sustituido opcionalmente con uno a tres sustituyentes seleccionados de forma independiente del grupo formado por Cl, F, CH3, OCH3, OCF3 y CF3; o X11 y X12 se toman en conjunto para formar -(CH2)r-L1-(CH2)r-; L1 es C(X2)(X2), O, S(O)m o N(X2), r cada vez que se da es de forma independiente 1, 2 o 3; X2 cada vez que se da es de forma independiente H, un alquilo C1-6 opcionalmente sustituido o un cicloalquilo C3-7 opcionalmente sustituido, donde el alquilo c1-6 opcionalmente sustituido y el cicloalquilo C3-7 opcionalmente sustituido de la definicion de X2 están opcionalmente sustituidos de forma independiente con -S(O)m-alquilo C1-6, -C(O)OX3, 1 a 5 halogenos o 1 a 3 OX3; X3 cada vez que se da es de forma independiente H, o alquilo C1-6, X6 cada vez que se da es de forma independiente H, alquilo C1-6 opcionalmente sustituido, alquilo C2-6 halogenado, cicloalquilo C3-7 opcionalmente sustituido, cicloalquilo C3-7 halogenado, donde el alquilo C1-6 opcionalmente sustituido y el cicloalquilo C3-7 opcionalmente sustituido de la definicion de X6 están opcionalmente sustituidos de forma independiente con hidroxilo, alcoxilo C1-4, carboxilo, CONH2, -S(O)m-alquilo C1-6, -CO2alquil C1-4, 1H-tetrazol- 5-ilo o 1 o 2 alquilos C1-4; o cuando hay dos grupos X6 en un átomo y los dos X6 son alquilo C1-6, los dos grupos alquilo C1-6 podrían estar opcionalmente unidos y, junto con el átomo al que están unidos los dos grupos X6, formar un anillo de 4 a 9 miembros que opcionalmente tenga O, s o NX7; X7 es h o alquilo c1-6 opcionalmente sustituido con hidroxilo; y m cada vez que se da es de forma independiente 0,m 1 o 2; con la condicion de que: X6 y X12 no pueden ser H cuando se unen a C(O) o SO2 en forma de C(O)X6, C(O)X12, SO2X6 o SO2X12; y cuando R2 es H entonces R1 no es -CH=CH-fenilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US946995P | 1995-12-28 | 1995-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052506A2 true AR052506A2 (es) | 2007-03-21 |
Family
ID=21737850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960105571A AR004367A1 (es) | 1995-12-28 | 1996-12-09 | Compuestos heterociclicos, mezclas diastereomericas composiciones farmaceuticas, uso de los compuestos en la preparacion de medicamentos. |
| ARP060100824A AR052506A2 (es) | 1995-12-28 | 2006-03-03 | Intermediarios utiles para la preparacion de compuestos heterociclicos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960105571A AR004367A1 (es) | 1995-12-28 | 1996-12-09 | Compuestos heterociclicos, mezclas diastereomericas composiciones farmaceuticas, uso de los compuestos en la preparacion de medicamentos. |
Country Status (43)
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| CN101239089A (zh) | 1997-04-15 | 2008-08-13 | Csir公司 | 具有食欲抑制剂活性的药物组合物 |
| GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| ES2283055T3 (es) | 1997-06-25 | 2007-10-16 | Pfizer Inc. | Derivados dipeptidos como secretagogos de la hormona de crecimiento. |
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
| US6329342B1 (en) | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
| ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| US6893877B2 (en) * | 1998-01-12 | 2005-05-17 | Massachusetts Institute Of Technology | Methods for screening substances in a microwell array |
| KR20010034198A (ko) | 1998-01-16 | 2001-04-25 | 한센 핀 베네드 | 성장 호르몬 방출성을 가지는 화합물 |
| US6657063B1 (en) * | 1998-04-30 | 2003-12-02 | Pfizer Inc. | Combinations of β3 agonists and growth hormone secretagogues |
| HUP0102236A3 (en) * | 1998-06-03 | 2003-01-28 | Pfizer Prod Inc | 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors and pharmaceutical compositions containing them and their use |
| EA200001189A1 (ru) * | 1998-06-16 | 2001-06-25 | Пфайзер Продактс Инк. | Терапевтические комбинации (избирательных) модуляторов рецепторов эстрогенов (имрэ) и стимуляторов секреции гормона роста (ссгр) для лечения скелетно-мышечной слабости |
| HN1999000097A (es) * | 1998-06-16 | 1999-11-03 | Pfizer Prod Inc | Terapia de combinacion para la fragilidad muscoloesqueletica |
| PA8471201A1 (es) * | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
| US6639076B1 (en) | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
| US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| EP1156808A2 (en) * | 1998-09-02 | 2001-11-28 | Merck & Co., Inc. | Enhancement of return to independent living status with a growth hormone secretagogue |
| JP4854114B2 (ja) | 1998-09-11 | 2012-01-18 | シュミドマイヤー，ゲルハルド | 生物学的に活性なインプラント |
| US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
| US6380184B1 (en) | 1998-10-28 | 2002-04-30 | Bristol-Myers Squibb Co. | Benzoazepines and analogs thereof useful as growth hormone secretagogues |
| US6194578B1 (en) * | 1998-11-20 | 2001-02-27 | Pfizer Inc. | Dipeptide derivatives |
| US6297380B1 (en) | 1998-11-23 | 2001-10-02 | Pfizer Inc. | Process and intermediates for growth hormone secretagogues |
| SI1004583T1 (en) * | 1998-11-23 | 2004-12-31 | Pfizer Products Inc. | Process and hydantoin intermediates for the synthesis of growth hormone secretagogues |
| KR100699404B1 (ko) | 1999-02-18 | 2007-03-23 | 가켄 세야쿠 가부시키가이샤 | 성장 호르몬 분비촉진제로서의 신규 아미드 유도체 |
| US6828331B1 (en) | 1999-02-19 | 2004-12-07 | Eli Lilly And Company | Growth hormone secretagogues |
| US6541634B2 (en) | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
| US6525203B1 (en) | 1999-03-12 | 2003-02-25 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| US6518292B1 (en) | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
| EP1204321B1 (en) * | 1999-07-26 | 2005-11-09 | Baylor College Of Medicine | Super-active porcine growth hormone releasing hormone analog |
| GB2396815B (en) | 1999-10-27 | 2004-09-08 | Phytopharm Plc | A composition comprising a pregnenone derivative and an NSAID |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| ATE304373T1 (de) * | 1999-12-28 | 2005-09-15 | Kaken Pharma Co Ltd | Nervenschutzmittel |
| US20020151040A1 (en) | 2000-02-18 | 2002-10-17 | Matthew O' Keefe | Apparatus and methods for parallel processing of microvolume liquid reactions |
| US7332271B2 (en) * | 2000-02-18 | 2008-02-19 | Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for parallel processing of micro-volume liquid reactions |
| EP1132388A3 (en) | 2000-03-09 | 2004-03-03 | Pfizer Products Inc. | Hexahydropyrazolo[4,3-c]pyridine metabolites |
| EP1149583A3 (en) * | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
| ES2252230T3 (es) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento. |
| DOP2001000154A (es) * | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
| AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
| ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| IL143690A0 (en) * | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| EP1181933A3 (en) * | 2000-06-29 | 2002-04-10 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating or increasing appetite |
| IL143942A0 (en) * | 2000-06-29 | 2002-04-21 | Pfizer Prod Inc | Use of growth hormone secretagogues for treatment of physical performance decline |
| GB2363985B (en) | 2000-06-30 | 2004-09-29 | Phytopharm Plc | Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use |
| IL144468A0 (en) * | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| JP2004507502A (ja) * | 2000-08-30 | 2004-03-11 | ファイザー・プロダクツ・インク | 成長ホルモン分泌促進物質のための徐放性製剤 |
| EP1192943A3 (en) * | 2000-09-28 | 2002-11-27 | Pfizer Products Inc. | Use of growth hormone secretagogues in conjunction with physical exercise |
| US20100261159A1 (en) | 2000-10-10 | 2010-10-14 | Robert Hess | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
| US6716629B2 (en) * | 2000-10-10 | 2004-04-06 | Biotrove, Inc. | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
| CA2347330C (en) * | 2001-05-10 | 2002-03-12 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
| US7125840B2 (en) | 2001-10-09 | 2006-10-24 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
| WO2003041641A2 (en) | 2001-11-09 | 2003-05-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| US20030199514A1 (en) * | 2002-03-27 | 2003-10-23 | Fryburg David A. | Methods for improving efficacy of treatment with growth hormone secretagogues |
| ATE332307T1 (de) * | 2002-04-09 | 2006-07-15 | Lilly Co Eli | Wachstumhormonsekretionsförderer |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US8277753B2 (en) | 2002-08-23 | 2012-10-02 | Life Technologies Corporation | Microfluidic transfer pin |
| CN1688696A (zh) * | 2002-09-18 | 2005-10-26 | 蒙特利尔大学医疗中心 | Ghrh类似物 |
| CA2521999A1 (en) | 2002-12-20 | 2004-09-02 | Biotrove, Inc. | Assay apparatus and method using microfluidic arrays |
| US20060094108A1 (en) * | 2002-12-20 | 2006-05-04 | Karl Yoder | Thermal cycler for microfluidic array assays |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004108120A1 (en) * | 2003-06-11 | 2004-12-16 | Pfizer Products Inc. | Use of growth hormone secretagogues for treatment of fibromyalgia |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| EP1669350B1 (en) | 2003-09-22 | 2012-02-29 | Msd K.K. | Piperidine derivatives |
| US7129561B2 (en) * | 2003-11-19 | 2006-10-31 | International Business Machines Corporation | Tri-metal and dual-metal stacked inductors |
| JP2007529015A (ja) | 2004-03-12 | 2007-10-18 | バイオトローブ， インコーポレイテッド | ナノリットルのアレイローディング |
| JP2007531739A (ja) * | 2004-04-02 | 2007-11-08 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | スルホンアミドおよびそれらの使用 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| WO2005097174A2 (en) * | 2004-04-07 | 2005-10-20 | Gastrotech Pharma A/S | Uses of a combination of ghrelin and somatotropin for the treatment of cachexia |
| AU2005266448A1 (en) | 2004-07-28 | 2006-02-02 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
| US20060105453A1 (en) | 2004-09-09 | 2006-05-18 | Brenan Colin J | Coating process for microfluidic sample arrays |
| US12070731B2 (en) | 2004-08-04 | 2024-08-27 | Life Technologies Corporation | Methods and systems for aligning dispensing arrays with microfluidic sample arrays |
| KR101380200B1 (ko) * | 2004-08-12 | 2014-04-01 | 헬신 세라퓨틱스 (유.에스.) 인크. | 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을촉진하는 방법 |
| EP2389941A1 (en) | 2004-08-18 | 2011-11-30 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
| EP1892241B1 (en) | 2005-05-30 | 2016-03-30 | Msd K.K. | Novel piperidine derivative |
| JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
| JPWO2007024004A1 (ja) | 2005-08-24 | 2009-03-05 | 萬有製薬株式会社 | フェニルピリドン誘導体 |
| US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
| WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| WO2007048027A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
| CA2629018C (en) | 2005-11-10 | 2013-12-31 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
| KR20080075530A (ko) * | 2005-11-21 | 2008-08-18 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 그렐린, 그 유도체 또는 ＧＨＳ-Ｒ1ａ에 작용하는 물질을유효 성분으로 포함하는 피부 수복 촉진 치료제 |
| US8273702B2 (en) * | 2006-02-17 | 2012-09-25 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| CU23592A1 (es) * | 2006-02-28 | 2010-11-11 | Ct Ingenieria Genetica Biotech | Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6 |
| US20100227806A1 (en) | 2006-03-10 | 2010-09-09 | Tulipano Giovanni | Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment |
| EP3056509A1 (en) * | 2006-09-08 | 2016-08-17 | Piramal Imaging SA | Bombesin analogues for use in diagnosis |
| WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
| AU2007301126A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| KR20090085599A (ko) * | 2006-10-02 | 2009-08-07 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Ｐｅｔ 영상화용 규소 유도체 |
| US20080114055A1 (en) * | 2006-11-10 | 2008-05-15 | Zoltan Laboratories Llc | Thioxanthone Compounds to Reverse Weight Loss |
| ES2604943T3 (es) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos |
| BRPI0721424A2 (pt) * | 2007-03-01 | 2014-03-25 | Bayer Schering Pharma Ag | Métodos de radiofluoração |
| ATE518544T1 (de) | 2007-03-12 | 2011-08-15 | Zadec Aps | Rotbusch-extrakt gegen diabetes |
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2008151512A1 (fr) * | 2007-06-12 | 2008-12-18 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Dérivés de calcitonine de saumon linéaires, pégylés, spécifiques de site |
| JPWO2009110510A1 (ja) | 2008-03-06 | 2011-07-14 | Ｍｓｄ株式会社 | アルキルアミノピリジン誘導体 |
| US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2741644C (en) | 2008-10-30 | 2013-05-07 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
| EP2305679A1 (en) | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| EP2361912A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| EP2361911A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| BR112012020377B1 (pt) * | 2010-02-26 | 2019-10-08 | Raqualia Pharma Inc. | Uso de um composto ou sal farmaceuticamente aceitável do mesmo e embalagem comercial |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
| CA2833434A1 (en) * | 2011-04-21 | 2012-10-26 | Theratechnologies Inc. | Growth hormone releasing factor (grf) analogs and uses thereof |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| WO2013175805A1 (en) * | 2012-05-25 | 2013-11-28 | Raqualia Pharma Inc. | Ghrelin receptor agonists for the treatment of achlorhydria |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2959427T3 (es) | 2012-09-27 | 2024-02-26 | Elanco Animal Health Incorporated | Composiciones farmacéuticas para el tratamiento de la inapetencia |
| JP6262661B2 (ja) | 2012-10-24 | 2018-01-17 | 第一三共株式会社 | 筋萎縮性側索硬化症治療剤 |
| EP2958562B1 (en) | 2013-02-22 | 2025-09-10 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| WO2014192294A1 (en) * | 2013-05-28 | 2014-12-04 | Raqualia Pharma Inc. | Polymorph forms |
| RS65632B1 (sr) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Ltd | Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe |
| KR102051433B1 (ko) * | 2013-08-27 | 2020-01-08 | (주)네오팜 | 근육 분화 촉진 및 근육 강화용 조성물 및 외용제 |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| KR101980180B1 (ko) * | 2014-08-05 | 2019-05-20 | 라퀄리아 파마 인코포레이티드 | 그렐린 수용체 작용제로서의 세린 유도체 |
| CN113121450A (zh) | 2014-08-29 | 2021-07-16 | Tes制药有限责任公司 | α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂 |
| US9901571B2 (en) | 2014-10-31 | 2018-02-27 | Raqualia Pharma Inc. | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| US20180134667A1 (en) | 2016-10-14 | 2018-05-17 | TES Pharma S.r.I. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| IL283182B2 (en) | 2018-11-20 | 2025-10-01 | Tes Pharma S R L | Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors |
| CN109320515A (zh) * | 2018-11-22 | 2019-02-12 | 常州大学 | 一种Capromorelin手性中间体的不对称合成方法 |
| WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| CN120265641A (zh) * | 2023-04-21 | 2025-07-04 | 长春金赛药业有限责任公司 | GHSR 1a激动剂、药物组合物及其制备方法和应用 |
| CN119285632A (zh) * | 2024-10-09 | 2025-01-10 | 威海中腾医药科技有限公司 | 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI55343C (fi) * | 1971-05-11 | 1979-07-10 | Sandoz Ag | Foerfarande foer framstaellning av nya, blodtryckssaenkande 3-hydrazinopyrido(4,3-c)pyridazinderivat |
| DE2221808C2 (de) * | 1972-05-04 | 1985-06-20 | Sandoz-Patent-GmbH, 7850 Lörrach | Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel |
| IL107836A (en) * | 1992-12-11 | 1998-01-04 | Merck & Co Inc | Spiro piperidines and homologues, their preparation and pharmaceutical preparations containing them |
| JP3670690B2 (ja) * | 1993-10-04 | 2005-07-13 | トーアエイヨー株式会社 | ３−ピリダジノン誘導体、その製造法およびそれを含有する循環器官用剤 |
| WO1995011029A1 (en) * | 1993-10-19 | 1995-04-27 | Merck & Co., Inc. | Combination of bisphosphonates and growth hormone secretagogues |
| JPH10506091A (ja) * | 1993-11-09 | 1998-06-16 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモン放出促進性のピペリジン、ピロリジンおよびヘキサヒドロ−１ｈ−アゼピン類 |
| US5935924A (en) * | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
| US5610134A (en) * | 1994-04-15 | 1997-03-11 | Genentech, Inc. | Treatment of congestive heart failure |
| US5767118A (en) * | 1994-10-26 | 1998-06-16 | Merck & Co., Inc. | 4-Heterocyclic peperidines promote release of growth hormone |
| US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
| AU705744B2 (en) * | 1995-01-27 | 1999-06-03 | Sapphire Therapeutics, Inc. | Compounds with growth hormone releasing properties |
| WO1996024587A1 (en) * | 1995-02-09 | 1996-08-15 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| AU4534596A (en) * | 1995-02-09 | 1996-08-27 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| AU6772996A (en) * | 1995-08-21 | 1997-03-12 | Eli Lilly And Company | 2-acylaminopropanamides as growth hormone secretagogues |
| AU6724496A (en) * | 1995-08-21 | 1997-03-12 | Eli Lilly And Company | 2-acylaminopropanamines as growth hormone secretagogues |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
-
1996
- 1996-11-13 TW TW085113857A patent/TW432073B/zh not_active IP Right Cessation
- 1996-11-14 AP APAP/P/1996/000881A patent/AP756A/en active
- 1996-12-04 CA CA002241725A patent/CA2241725C/en not_active Expired - Lifetime
- 1996-12-04 IL IL13891096A patent/IL138910A0/xx unknown
- 1996-12-04 DK DK96938434T patent/DK0869968T3/da active
- 1996-12-04 KR KR10-1998-0704973A patent/KR100320167B1/ko not_active Expired - Lifetime
- 1996-12-04 SI SI9630755T patent/SI0869968T1/sl unknown
- 1996-12-04 HU HU9901246A patent/HUP9901246A3/hu unknown
- 1996-12-04 EP EP96938434A patent/EP0869968B1/en not_active Expired - Lifetime
- 1996-12-04 UA UA98063368A patent/UA66754C2/xx unknown
- 1996-12-04 DE DE69637063T patent/DE69637063T2/de not_active Expired - Lifetime
- 1996-12-04 TR TR1998/01233T patent/TR199801233T2/xx unknown
- 1996-12-04 CN CN96199388A patent/CN1113895C/zh not_active Expired - Lifetime
- 1996-12-04 IL IL12444996A patent/IL124449A/en not_active IP Right Cessation
- 1996-12-04 AT AT96938434T patent/ATE361314T1/de not_active IP Right Cessation
- 1996-12-04 SK SK874-98A patent/SK285678B6/sk not_active IP Right Cessation
- 1996-12-04 PT PT96938434T patent/PT869968E/pt unknown
- 1996-12-04 CZ CZ19981995A patent/CZ293423B6/cs not_active IP Right Cessation
- 1996-12-04 ES ES96938434T patent/ES2285715T3/es not_active Expired - Lifetime
- 1996-12-04 JP JP52412497A patent/JP3511382B2/ja not_active Expired - Lifetime
- 1996-12-04 PL PL96327634A patent/PL186916B1/pl not_active IP Right Cessation
- 1996-12-04 AU AU75850/96A patent/AU716934B2/en not_active Ceased
- 1996-12-04 IL IL13890996A patent/IL138909A0/xx unknown
- 1996-12-04 IL IL138911A patent/IL138911A/en not_active IP Right Cessation
- 1996-12-04 NZ NZ322172A patent/NZ322172A/xx unknown
- 1996-12-04 BR BRPI9612465-2A patent/BR9612465B1/pt not_active IP Right Cessation
- 1996-12-04 WO PCT/IB1996/001353 patent/WO1997024369A1/en not_active Ceased
- 1996-12-06 HN HN1996000085A patent/HN1996000085A/es unknown
- 1996-12-09 AR ARP960105571A patent/AR004367A1/es active IP Right Grant
- 1996-12-19 GT GT199600100A patent/GT199600100A/es unknown
- 1996-12-20 CO CO96066996A patent/CO4480108A1/es unknown
- 1996-12-23 ZA ZA9610858A patent/ZA9610858B/xx unknown
- 1996-12-24 EG EG117796A patent/EG24195A/xx active
- 1996-12-24 MA MA24438A patent/MA26415A1/fr unknown
- 1996-12-24 TN TNTNSN96172A patent/TNSN96172A1/fr unknown
- 1996-12-26 RS YUP-702/96A patent/RS49926B/sr unknown
- 1996-12-26 MY MYPI96005499A patent/MY135727A/en unknown
- 1996-12-27 PE PE1996000961A patent/PE30398A1/es not_active Application Discontinuation
- 1996-12-27 HR HR960618A patent/HRP960618B1/xx not_active IP Right Cessation
-
1997
- 1997-01-27 SA SA97170581A patent/SA97170581B1/ar unknown
-
1998
- 1998-05-26 IS IS4758A patent/IS4758A/is unknown
- 1998-06-11 BG BG102533A patent/BG64055B1/bg unknown
- 1998-06-19 OA OA9800090A patent/OA10702A/en unknown
- 1998-06-24 MX MX9805157A patent/MX9805157A/es active IP Right Grant
- 1998-06-26 NO NO19982991A patent/NO325135B1/no not_active IP Right Cessation
-
1999
- 1999-03-01 US US09/258,956 patent/US6110932A/en not_active Expired - Lifetime
- 1999-03-01 US US09/259,691 patent/US6107306A/en not_active Expired - Lifetime
- 1999-03-01 US US09/259,776 patent/US6124264A/en not_active Expired - Lifetime
- 1999-05-27 AP APAP/P/1999/001555A patent/AP860A/en active
- 1999-12-22 US US09/470,668 patent/US6278000B1/en not_active Expired - Lifetime
-
2000
- 2000-06-13 US US09/593,582 patent/US6306875B1/en not_active Expired - Lifetime
- 2000-06-13 US US09/593,581 patent/US6313140B1/en not_active Expired - Lifetime
- 2000-12-11 US US09/734,274 patent/US6482825B2/en not_active Expired - Lifetime
- 2000-12-20 JP JP2000386997A patent/JP2001213800A/ja active Pending
-
2006
- 2006-03-03 AR ARP060100824A patent/AR052506A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR052506A2 (es) | Intermediarios utiles para la preparacion de compuestos heterociclicos | |
| AR049284A1 (es) | Compuestos derivados de 1,3-tiazol; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas a la actividad de los ppard | |
| AR078508A1 (es) | Derivados spiro [2.4]heptano puenteados, composiciones farmaceuticas y uso de los mismos | |
| ES2562279T3 (es) | Formulaciones de apixabán | |
| AR121914A1 (es) | Compuestos útiles para inhibir la quinasa ret | |
| CL2004000382A1 (es) | Tetrahidroisoquinolinas sustituidas, proceso de preparacion, y composicion farmaceutica, utiles en el tratamiento y prevencion de estados patologicos que se alivian con un agonista de 5-ht6. | |
| AR066880A1 (es) | Acidos benzoilamino-idan-2-carboxilicos sustituidos y compuestos relacionados | |
| AR064657A1 (es) | 8- alquinilxantinas y derivados | |
| JP2016517851A5 (es) | ||
| AR035612A1 (es) | 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa | |
| AR069512A1 (es) | Pirazolopirimidinas sustituidas para el tratamiento de trastornos del snc. composiciones farmaceuticas | |
| GT200000216A (es) | Oxazolidinonas sustituidas y su uso. | |
| CA2387486C (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders | |
| JP2004531531A5 (es) | ||
| AR038366A1 (es) | Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion | |
| RU2018142988A (ru) | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена | |
| AR045879A1 (es) | Uso de un antagonista del receptor nk3 para preparar una composicion farmaceutica | |
| AR084430A1 (es) | Di/tri-aza-espiro-alcanos c | |
| JP2018528229A5 (es) | ||
| AR032778A1 (es) | Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento | |
| RU2003133216A (ru) | Фармацевтические комбинации | |
| AR048334A1 (es) | Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta. | |
| JP2014530197A5 (es) | ||
| DK0536269T3 (da) | Anvendelse af inositol-triphosphat til fremstilling af medikamenter | |
| RU2017133660A (ru) | Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |